{
    "nctId": "NCT06335069",
    "briefTitle": "18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.",
    "officialTitle": "18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer - a Pilot Study.",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer, Breast Neoplasms, Breast Diseases",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 10,
    "primaryOutcomeMeasure": "To investigate the accuracy of 68Ga-FAPI-46 compared to 18F-FDG as a radioactive PET tracer in patients with ER+ breast cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patient with histopathologically proven ER+ breast cancer.\n* Diagnosed with locally advanced (primary tumor \\>5 cm and/or presence of axillary lymph node metastases) or recurrent breast cancer, for which 18F-FDG PET/CT or 18F-FDG PET/MRI staging is performed.\n* Willing and able to undergo the study procedures.\n* Has personally provided written informed consent.\n\nExclusion Criteria:\n\n* Age \\<18\n* Pregnancy\n* Patients with secondary malignancies\n* No 18F-FDG PET/CT or 18F-FDG PET/MRI scan.\n* Contra-indications for PET/MRI such as pacemaker, aneurysm clips, metallic device in their body, severe claustrophobia, and severe obesity\n* Chronic inflammatory disease such as rheumatoid arthritis.\n* Patients with severe hepatic or renal impairment (eGFR \u226445mL/min/1.73m\u00b2)\n* Inability to provide informed consent.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}